Literature DB >> 2881419

Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations.

G A Spinas, J Zapf, A M Landolt, G Stuckmann, E R Froesch.   

Abstract

Five acromegalic patients were treated preoperatively over a period of 1-4 weeks with the somatostatin analogue SMS 201-995. The patients received daily 3 X 100 micrograms of SMS 201-995 subcutaneously. This schedule resulted in a rapid improvement of the clinical symptoms in 4 out of 5 patients. In these same patients plasma growth hormone concentrations decreased markedly. However, only in one patient were growth hormone concentrations normalized. Plasma IGF I, which was elevated in all patients, was normalized only in this same patient. Tumour volume as determined by thin section CT-scans decreased only in one case by 17%. All tumours appeared extraordinarily soft upon operation. Conventional light microscopy showed no difference between tumours of SMS-pre-treated and untreated patients. Ultrastructural investigation showed the usual heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881419     DOI: 10.1530/acta.0.1140249

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  6 in total

Review 1.  Is presurgical treatment with somatostatin analogs necessary in acromegalic patients?

Authors:  M Losa; P Mortini; M Giovanelli
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

Review 2.  Pharmacotherapy or surgery as primary treatment for acromegaly?

Authors:  D Ferone; A Colao; A J van der Lely; S W Lamberts
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

Review 3.  Current status and future opportunities for controlling acromegaly.

Authors:  Shlomo Melmed; Mary Lee Vance; Ariel L Barkan; Bengt-Ake Bengtsson; David Kleinberg; Anne Klibanski; Peter J Trainer
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 4.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 5.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 6.  Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis.

Authors:  Francisco Pita-Gutierrez; Sonia Pertega-Diaz; Salvador Pita-Fernandez; Lara Pena; Gloria Lugo; Susana Sangiao-Alvarellos; Fernando Cordido
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.